Hologic Expands Fibroid Treatment Portfolio with $350M Gynesonics Acquisition

Hologic announced on Monday its $350 million acquisition of Gynesonics, a company specializing in non-invasive treatments for uterine fibroids. Gynesonics’ Sonata system uses ultrasound and radiofrequency energy to treat fibroids without requiring incisions. Clinical trials revealed that 88% of patients reported reduced symptoms three years post-treatment.

​

This acquisition positions Hologic to enhance its offerings, particularly by complementing its existing Acessa ProVu system, which requires three incisions for similar results. Analysts from William Blair highlighted that this deal aligns with Hologic's strategy of acquiring early-stage growth assets. Uterine fibroids affect over 70% of white women and more than 80% of Black women in the U.S. before menopause, many of whom seek less invasive treatment options. The Sonata system, which was FDA-cleared in 2018, provides a promising alternative with a swift recovery time of just over two days.

​

Earlier this year, Gynesonics raised $67 million to support commercialization, and the addition of their system to Hologic's portfolio should drive further growth. Hologic's recent purchases, including its $310 million acquisition of Endomagnetics, reflect its commitment to expanding its portfolio through strategic acquisitions.